Cubist Systematic Strategies, LLC Dyne Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$13.06 - $29.18 $559,190 - $1.25 Million	42,817 New	42,817 $1.22 Million
Q1 2023 May 15, 2023	SELL	$10.88 - $15.0 $23,413 - $32,280	-2,152 Reduced 7.32%	27,240 $313,000
Q4 2022 Feb 14, 2023	BUY	$9.37 - $13.8 $22,131 - $32,595	2,362 Added 8.74%	29,392 $340,000
Q3 2022 Nov 14, 2022	BUY	$7.2 - $15.17 $193,492 - $407,678	26,874 Added 17226.92%	27,030 $343,000
Q3 2022 Nov 14, 2022	BUY	$7.2 - $15.17 $193,492 - $407,678	26,874 Added 17226.92%	27,030 $343,000
Q2 2022 Aug 15, 2022	SELL	$4.36 - $10.5 $5,044 - $12,148	-1,157 Reduced 88.12%	156 $1,000
Q1 2022 May 16, 2022	SELL	$6.52 - $12.27 $78,037 - $146,859	-11,969 Reduced 90.11%	1,313 $13,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $16.07 $58,308 - $78,807	4,904 Added 58.53%	13,282 $158,000
Q3 2021 Nov 15, 2021	BUY	$15.6 - $21.46 $116,469 - $160,220	7,466 Added 818.64%	8,378 $136,000
Q2 2021 Aug 16, 2021	BUY	$15.94 - $22.33 $14,537 - $20,364	912 New	912 $19,000
Q1 2021 May 17, 2021	SELL	$14.0 - $29.3 $140,434 - $293,908	-10,031 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$16.81 - $23.94 $168,621 - $240,142	10,031 New	10,031 $211,000

210

102M

234K

238K

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.55B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.